Guardian Pharmacy Services, Inc. Class A (GRDN)
NYSE:GRDN
GRDN Stock Chart & Stats
$39.49
$0.47(2.39%)
At close: 4:00 PM EST
$39.49
$0.47(2.39%)
Day’s Range― - ―
52-Week Range$19.17 - $41.36
Previous Close$20.98
Volume93.63K
Average Volume (3M)348.83K
Market Cap
$2.48B
Enterprise Value$2.48B
Total Cash (Recent Filing)$65.62M
Total Debt (Recent Filing)$44.72M
Price to Earnings (P/E)38.1
Beta0.68
Next Earnings
May 18, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding36,259,760
10 Day Avg. Volume450,542
30 Day Avg. Volume348,833
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit8.79
Enterprise Value/Ebitda24.14
Forecast
1Y Price Target
$43.50Price Target Upside10.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.24
Revenue Forecast (FY)$1.41B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLeverage fell markedly by 2025, leaving the company with a conservative capital structure and a larger equity base. Lower debt reduces interest burden and liquidity strain, increasing resilience to industry shocks and providing durable optionality for disciplined M&A or investment over the next several quarters.
Consistent Cash GenerationPersistent positive operating and free cash flow with a large year‑end cash build strengthens funding capacity for growth and working capital. High cash conversion gives management flexibility to fund greenfields, acquisitions, and absorb policy-driven margin pressure without immediate refinancing risk.
Scale & EBITDA MomentumSteady revenue scale (~$1.4–1.45B) plus operating leverage drove material EBITDA improvement and a raised 2026 EBITDA target. Scale in long‑term care pharmacy and improved vaccine economics support structural margin gains and durable operating efficiency as the business grows.
Bears Say
Policy/IRA HeadwindThe IRA introduces sustained pricing and reimbursement pressure; management specifically flagged a sizable, multi‑year branded drug negotiation impact. This structural policy risk can compress revenue and margin visibility, forcing ongoing cost or strategy responses over multiple fiscal years.
Earnings VolatilityWide swings between a material 2024 loss and 2025 recovery indicate operating sensitivity to payor dynamics, one‑time items, and working‑capital swings. Persistent earnings volatility undermines forecasting, capital allocation and confidence in sustainable margins absent clearer trend stability.
Margin Drag From M&A & GreenfieldsExpansion via acquisitions and new sites is accelerating top‑line but is dilutive to near‑term margins while locations ramp. Integration and startup costs, plus an expected step‑up in compensation expense, pose a sustained drag until scale efficiencies fully materialize and can pressure medium‑term profitability.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $19.17 and its highest was $41.36 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.48B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is May 18, 2026 which is in 33 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on Mar 11, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.268 by $0.102.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.24.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 36,259,760 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.37 in its last earnings report, beating expectations of $0.268. Following the earnings report the stock price went down -0.716%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.50 (10.15% Upside)
$43.50 (10.15% Upside)
Hedge Fund Trend
Decreased
By 81.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $419.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.50%
12-Months-Change
Fundamentals
Return on Equity
25.85%
Trailing 12-Months
Asset Growth
12.07%
Trailing 12-Months
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple strong operating and financial achievements—solid organic and reported revenue growth, meaningful adjusted EBITDA expansion, improved gross margins, strong cash generation, measurable clinical impact, and raised 2026 EBITDA guidance. Management acknowledged material industry headwinds from the IRA, one-time favorable Q4 variability, margin drag from early-stage acquisitions and greenfields, and ongoing operational complexity from new Medicare processes. Overall, the company appears to be executing well, generating cash, and positioning to offset near-term policy impacts, while remaining cautious and disciplined on M&A amid industry disruption.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$43.50
▲(10.15% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---